May. 15 at 9:01 PM
$SLS GPS P3 Results are worth - truly worth
$40B + the Instant the REGAL Results are announced
- GPS MOS 30 - 36 months, BAT 8-10
--- T1 Trading Halt - Gap Up into the
$10B MCap Range /
$50 Per Share Range
- AND CLIMBING
And to Bottom LINE 009 / TAMBICICLIB Will Be FDA Approved
- the Market Has yet to appreciate its value.
Gleevc - Imatinib
Imbrutinib - Imbruvica
Upadactinib - Rinvoq Upadactinib <- say that 3 x fast
$PFE Pfizers' Ibrance - Palbociclib CDKinase Inhibitor
$NVS Novartis' Kisqali -Ribociclib CDKinase Inhibitor
$LLY Eli Lilly's Verzenio - Abemaciclib CDKinase Inhibitor
$SLS ufTambiciclib CDKInase Inhibitor.
https://www.reddit.com/r/sellasLifescience/search/?q=aml-mr&cId=057d1aab-2b7d-4bf0-a2d4-c3227af101f8&iId=8d5110f2-0189-40ea-bc04-b363b5cad724 for anyone interested in DD/ i been here invested a long time/ if you have an interest in understanding why 009 / Gps these SLS Shares are trading / short / warrant manipulative share price management -reality is GPS P3 Results are now Imminent and - truly worth
$40B + the moment the REGAL Trial Results are announced.